Beyond Biotech - the podcast from Labiotech

Can cell therapy tackle hearing loss?

May 31, 2024 Labiotech
Can cell therapy tackle hearing loss?
Beyond Biotech - the podcast from Labiotech
More Info
Beyond Biotech - the podcast from Labiotech
Can cell therapy tackle hearing loss?
May 31, 2024
Labiotech

Hearing loss is a huge – and growing – global challenge.

Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge. 

The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. The company is looking to start first-in-human trials in 2025.

Today, on the podcast we have a conversation with Rinri CEO Simon Chandler about the different kinds of hearing loss, what’s being done to tackle them, and Rinri’s novel approach to treatments.

01:08-03:19: About Rinri Therapeutics
03:19-05:16: About hearing loss
05:16-07:31: Mental health and hearing loss
07:31-10:22: The different kinds of hearing loss
10:22-11:37: The importance of early intervention
11:37-13:46: What is Rinri doing to tackle hearing loss?
13:46-15:58: The difficulty of accessing the cochlea
15:58-19:12: Is your treatment a cure for hearing loss?
19:12-20:45: Would repeat treatment be necessary?
20:45-23:30: Are other companies working on hearing loss?
23:30-25:27: The cost of treating hearing loss
25:27-27:13: The economic costs of hearing loss
27:13-28:33: Rinri treatment timelines
28:33-30:15: The rest of Rinri’s pipeline

 Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter


Show Notes Chapter Markers

Hearing loss is a huge – and growing – global challenge.

Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge. 

The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. The company is looking to start first-in-human trials in 2025.

Today, on the podcast we have a conversation with Rinri CEO Simon Chandler about the different kinds of hearing loss, what’s being done to tackle them, and Rinri’s novel approach to treatments.

01:08-03:19: About Rinri Therapeutics
03:19-05:16: About hearing loss
05:16-07:31: Mental health and hearing loss
07:31-10:22: The different kinds of hearing loss
10:22-11:37: The importance of early intervention
11:37-13:46: What is Rinri doing to tackle hearing loss?
13:46-15:58: The difficulty of accessing the cochlea
15:58-19:12: Is your treatment a cure for hearing loss?
19:12-20:45: Would repeat treatment be necessary?
20:45-23:30: Are other companies working on hearing loss?
23:30-25:27: The cost of treating hearing loss
25:27-27:13: The economic costs of hearing loss
27:13-28:33: Rinri treatment timelines
28:33-30:15: The rest of Rinri’s pipeline

 Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter


About Rinri Therapeutics

About hearing loss
Mental health and hearing loss

The different kinds of hearing loss
The importance of early intervention

What is Rinri doing to tackle hearing loss?

The difficulty of accessing the cochlea

Is your treatment a cure for hearing loss?

Would repeat treatment be necessary?

Are other companies working on hearing loss?

The cost of treating hearing loss

The economic costs of hearing loss

Rinri treatment timelines

The rest of Rinri’s pipeline